**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 46628

**Manuscript Type:** MINIREVIEWS

**Antidiabetic treatment on memory and spatial learning: From the pancreas to the neuron**

Xourgia E *et al*. Antidiabetic treatment on memory and spatial learning

Eleni Xourgia, Athanasia Papazafiropoulou, Andreas Melidonis

**Eleni Xourgia, Athanasia Papazafiropoulou, Andreas Melidonis** 1st Department of Internal Medicine and Diabetes Center, Tzaneio General Hospital of Piraeus, Athens 18536, Greece

**ORCID number:** Eleni Xourgia (0000-0001-5766-3209); Athanasia Papazafiropoulou (0000-0002-7596-4942); Andreas Melidonis (0000-0003-0505-5708).

**Author contributions:** All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Conflict-of-interest statement:** No potential conflicts of interest. No financial support.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author: Athanasia Papazafiropoulou, MD, MSc, PhD,** **Attending Doctor, Research Scientist,** 1st Department of Internal Medicine and Diabetes Center, Tzaneio General Hospital of Piraeus, 1 Zanni and Afentouli Street, Athens 18536, Greece. pathan@ath.forthnet.gr

**Telephone:** +30-697-996483

**Received:** February 20, 2019

**Peer-review started:** February 20, 2019

**First decision:** February 26, 2019

**Revised:** March 1, 2019

**Accepted:** March 8, 2019

**Article in press:** March 8, 2019

**Published online:** March 15, 2019

**Abstract**

The detrimental effects of constant hyperglycemia on neural function have been quantitatively and qualitatively evaluated in the setting of diabetes mellitus. Some of the hallmark features of diabetic encephalopathy (DE) are impaired synaptic adaptation and diminished spatial learning capacity. Chronic and progressive cognitive dysfunction, perpetuated by several positive feedback mechanisms in diabetic subjects, facilitates the development of early-onset dementia and Alzheimer’s disease. Despite the numerous clinical manifestations of DE having been described in detail and their pathophysiological substrate having been elucidated in both type 1 and type 2 diabetes mellitus, an effective therapeutic approach is yet to be proposed. Therefore, the aim of this review is to summarize the growing body of evidence concerning the effect of current antidiabetic treatment options on diabetic and non-DE.

**Key words:** Memory; Spatial learning; Cognitive; Neural remodeling; Type 2 diabetes mellitus; Antidiabetic drugs

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** In this review, we aim to create a concise overview of the effects exerted by hyperglycemia on neural tissue, while describing the potential of each antidiabetic drug to improve functional and cognitive capacity in subjects with diabetic encephalopathy.

**Citation:** Xourgia E, Pazafiropoulou A, Melidonis A. Antidiabetic treatment on memory and spatial learning: From the pancreas to the neuron. *World J Diabetes* 2019; 10(3): 169-180

**URL:** https://www.wjgnet.com/1948-9358/full/v10/i3/169.htm

**DOI:** https://dx.doi.org/10.4239/wjd.v10.i3.169

**INTRODUCTION**

Diabetic encephalopathy (DE) is defined as a complex combination of central nervous system (CNS) structural and functional changes, stemming mostly from oxidative stress and chronic inflammation of the neural tissue in the setting of long-standing hyperglycemia. While several mechanisms have been proposed for the explanation of cognitive decline in diabetic subjects, the intricate interplay of various signaling pathways along with the numerous co-morbidities of patients with diabetes do not allow for a definite pathogenetic model to be proposed. Moreover, the pathophysiological substrate of type 2 diabetes mellitus (T2DM) encephalopathy appears to be different from that of T1DM DE[1]. Currently, despite the abundance of evidence of the subject, the molecular mechanisms implicated in the development of DE and its rate of progression have not been clarified, resulting in a subsequent lack of treatment options for interruption or reversal of the cumulative neuronal damage and functional decline of patients. The purpose of our review is to summarize and describe the interaction between the various antidiabetic substances and DE, in order to facilitate the possible development of a therapeutic algorithm for affected patients.

**ENCEPHALOPATHY IN T2DM**

Several studies in T2DM subjects have confirmed the dysfunction of cognitive capacity, both in executive and processing tasks, when compared to healthy controls[2-5]. While the decline of neural capacity in T2DM is described as a multifactorial process, it is evident that tissue insulin resistance (IR) plays a pivotal role in the pathogenetic process. Insulin receptors are expressed in all major components of the CNS (neurons, microglia, astrocytes, oligodendrocytes and vascular system) in varying degrees. The downstream effects of insulin signaling in neural tissue include neurogenesis, apoptosis inhibition, cytokine release, attenuation of inflammatory response, vasodilation and glucogen uptake and storage[6]. While some researchers have proposed the possibility of de novo insulin synthesis in the CNS, current experimental data support the fact that the majority of centrally-acting hormone is produced at the pancreatic β-cells and subsequentlytransported through the blood brain barrier *via* the systemic circulation, with vascular endothelium significantly affecting the process[7]. The role of other peripherally-acting hormones such as glucagon-like peptide-1 (GLP-1), leptin or ghrelin on insulin transport and potency in the CNS has not been described so far. IR, defined as a dysfunction on any of the several stages preceding or during the signaling cascade activated by the insulin-receptor complex formation, can affect the homeostasis of all the processes described above that are mediated by the hormone.

**ANTIDIABETIC TREATMENT AND NEURAL FUNCTION**

***Biguanides***

The information surrounding metformin and its effect on cognitive impairment is contradictory and highly complex, varying between different types of test subjects and changing in accordance to different treatment dosages and pathophysiological substrates studied. On a cellular level, metformin exhibits pleiotropic effects, including interaction with multiple signaling pathways such as those of mitogen-activated protein kinases (MAPK) and mammalian target of rapamycin complex 1, that are closely linked to proliferation and apoptosis. Given the relative safety of the substance and its role in cellular turnover, the possibility of repurposing it for use in neurofunctional disorders is currently being investigated[8]. Chemical derivatives of metformin, such as HL271, induce comparable neuromodulatory effects, without any metabolic action, an indication that the drug effects may be only partially related to glucose homeostasis as is suggested in most of the experimental studies discussed on the following paragraphs[9].

Ou *et al*[10]designed anAlzheimer’s disease (AD) model in an effort to elucidate the anti-neuroinflammatory properties of metformin. APPswe/PS1ΔE9 mice underwent treatment with the biguanide, resulting into overall neuroprotective effects, with attenuation of spatial memory impairment, neural cellular proliferation, decreased local inflammation (both inflammatory cells and cytokines) of the brain cortex and the hippocampal region, as well as, reduced amyloid-β plaque deposition. The study results were attributed to drug-induced altered regulation of AMPK, mTOR, ribosomal protein S6 kinase, p65 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways[10].

Type 1 and 2 diabetes, induced in animal models through streptozotocin and high-fat diet respectively, have been linked to aberrant hippocampal neuroarchitecture with accompanying inflammation. Long-term metformin administration was shown to have a positive effect on hippocampal neural proliferation and memory function, despite the achieved hypoglycemic effect, a pathway mediated through interaction with insulin receptor substrate-1 *via* adenosine monophosphate (AMP) -kinase phosphorylation cascade activation[11].

Following a similar pattern of beneficial neural effects, on a diabetic rodent model where both memory and spatial recognition where evaluated with passive avoidance tasks and Y maze spontaneous alternation tests, metformin administration appeared to reverse the diabetes-induced functional decline[12]. Passive avoidance assesses the capacity of test subjects to avoid certain choices linked to painful stimuli, by use of their previous memory of similar situations, while the Y maze trial recruits several neural compartments and reviews the tendency of a subject for exploring new pathways, a process inherently linked to cognition. The treatment-mediated effects were attributed to numerous metabolic effects including achievement of normoglycemia, upregulation of vascular endothelial nitric oxide production, attenuation of oxidative damage and increased anti-apoptotic potential.

On a study including subjects with non-dementia vascular cognitive decline with impaired glucose homeostasis, the efficacy of donepezil when combined with either metformin or acarbose was evaluated as to the possible achievement of functional improvement. Carotid artery intima-media thickness (CA-IMT), cognitive capacity and IR where assessed at baseline and at 12 mo. The metformin-donepezil group showed superiority in the functional tests administered, a fact that can be attributed to the slower CA-IMT increase and decreased IR indexes when compared to the acarbose group, allowing for better neural tissue perfusion and metabolic signaling, respectively[13].

One of the several pathogenetic mechanisms explored in relation to DE, among other neurodegenerative processes, is autophagy dysfunction, leading to tissue-accumulation of non-functional peptides, in the form of aggravates. Chen *et al*[14] attempted to elucidate the effect of metformin administration on the regulation misfolded polypeptide clearance, by treating diabetic mice with an eight-week regimen of intraperitoneal metformin and/or chloroquine. Neural capacity was evaluated by the Morris water maze (MWM) test, while the presence of aggravates or abnormal tissue architecture were examined by histological preparations and immunochemistry. Biguanide treatment had a positive overall effect with enhancement of autophagy, reduction of hyperphosphorylated tau proteins and improved cognitive functionality, when compared to the control group[14].

Different treatment regimens comprising of metformin and ursolic acid combined or as monotherapy, as well as gliclazide were used by Mourya *et al*[15] in rodents with metabolic and cognitive impairment due to chronic restraint stress (containment for 2 h/d for 30 d). A total of 60 subjects were subdivided into 10 groups according to treatment protocol, with several metabolic parameters relative to cardiovascular function and IRs were observed. Behavioral and neurological performances were assessed by the MWM test. While insulin sensitivity and cognition were improved in all treatment groups, the most marked anti-inflammatory and neuroprotective effects were produced by the combination of metformin with ursolic acid, suggesting the existence of a synergistic effect between the two[15].

Metformin-induced neuromodulation has been studied on non-diabetic subjects as well, as is the case in the study of Fatemi *et al*[16], including a population of ovariectomized mice as the treatment group. Post-surgical subjects presented with cognitive impairment, anxiety disorders and reduced brain-derived neurotrophic factor (BDNF). Treatment with metformin had beneficial effects on behavioral dysfunction and BDNF reduction on both of the treatment groups (Group A: 7 mg/kg and Group B: 15 mg/kg). Reinforcing the idea that the neuroprotective effects of the biguanide class are not solely the result of metabolic normalization of glucose homeostasis[16].

As opposed to the aforementioned studies, Wennberg *et al*[17]found no correlation between metformin or other anti-diabetic treatments and cognitive capacity. T2DM subjects with lack of functional impairment at baseline (*n* = 508) were followed-up for a mean duration of 3.7 years. Mild cognitive impairment (MCI) diagnosis was defined as difference equal to or greater than 1 standard deviation than the age-specific mean score of the general population on each test administered. The study population was divided into 4 groups according to treatment type as following: insulin monotherapy, metformin monotherapy, other oral agents as monotherapy or diet and exercise without pharmacological intervention. A universal lack of positive effect on cognition was observed among all groups, with patients on metformin treatment having higher rates of MCI diagnosis at follow-up. The latter was attributed to vitamin B12 reduction secondary to long-standing metformin administration. While the results are validated by the size of the study population and the numerous validated cognitive tests performed, notable limitations such as partial correction of treatment group differences despite covariate consideration and propensity score utilization and lack of B12 measurement should be taken into consideration when evaluating the research conclusions[17].

Correspondingly, a study conducted on C57BL/6 mice of different age groups yielded neutral results concerning the effect of metformin on metabolic parameters while a negative, age-dependent, impact was observed on both spatial memory and visual acuity of the test subjects. Treatment regimen comprised of 2 mg metformin/mL of drinking water, which is analogous to a human dose of 1500-2000 mg/d (when converted in a body-weight dependent manner), for three months[18]. While, the contradicting results could be partially attributed to the short study duration there is further research with similar conclusions, in which metformin attenuated memory dysfunction in female subjects and amplified it in males, on an experimental model of AD[19].

The relationship between the class of biguanides and functional neural capacity remains unclear due to several relevant research projects with controversial results. At the same time, the underlying pathophysiological mechanisms by which metformin exerts its effects on neural tissue have not been, as of yet, entirely elucidated. While there appears to be a positive predilection towards the exploration of metformin administration as a form of neuroprotection, mainly due to its potency in altering a multitude of signaling pathways in the cell cycle, further research is needed in order to clarify whether it is truly efficacious in the clinical setting on patients with diabetes-induced cognitive decline.

***Alpha-glucosidase inhibitors***

Some of the main representors of the class of alpha-glucosidase inhibitors (α-GIs) are acarbose, miglitol and voglibose. Yan *et al*[20] administered acarbose to SAMP8 mice for a period of 6 mo. The study population was divided into 3 groups, including the acarbose group (*n* = 9, 9-mo old), young (*n* = 11, 3-mo old) and old controls (*n* = 8, 9-mo old). An age-dependent cognitive decline was observed when the control groups were compared, while the acarbose group showed attenuation of this decline, accompanied by higher levels of insulin, insulin receptors and acetylated histone H4 lysine 8 (H4K8ac). The altered functional phenotype of the acarbose group (less memory impairment, improved spatial recognition) was attributed to both the changes in the concentration of insulin and its receptor and the H4K8ac increase. Higher levels of the latter have been linked to ameliorated long-term memory formation[20].

Since the data concerning the neurological effect of α-GIs is scarce, with no relevant research including miglitol or voglibose, safe conclusions cannot be currently drawn for their possible actions on neural tissue.

***Sulphonylureas***

As far as the class of sulphonylureas (SUs) is concerned, there appears to be a lack of relevant clinical studies discussing their effects on the homeostatic regulation of the nervous system. Given their mode of action, through binding on adenosine triphosphate-sensitive potassium channels and the subsequent activation of voltage-gated calcium channels, their possible use for inducing and regulating neuroexcitatory potentials is an interesting perspective. Currently available research discussing the role of SUs in the setting of cognitive decline is centered on the use of glimepiride and glibenclamide.

Ishola *et al*[21] administered glimepiride on a rodent model of paraquat-induced Parkinsonism with subsequent functional and molecular assessment of the treatment-induced changes. Sulfonylurea treatment attenuated oxidative stress and activation of inflammatory cascades in the neural tissue, while, simultaneously, improving the paraquat-induced memory dysfunction and cognitive performance on the rotarod, open field and Y-maze trials[21].

Glibenclamide has been shown to exert long-term protective properties on the hippocampal cortex in the setting of traumatic brain injury (TBI)[22]. Moreover, the aforementioned exerted a beneficial effect when used on an experimental AD model, *via* regulating the activity of the hypothalamic-pituitary-adrenal axis and alleviating AD-related mood-disorders[23].

***Thiazolidinediones***

Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR) agonists, also widely known as glitazones, have been established to interact with the cell cycle and inflammatory cascade.

Pioglitazone was administered as monotherapy and in combination with simvastatin, on a model of lipopolysaccharide (LPS)-induced cognitive dysfunction secondary to amyloid deposition and inflammation. While LPS exacerbated neural oxidative stress, amyloid Aβ deposition, glutamate tissue-levels and memory impairment, both simvastatin and pioglitazone mitigated the changes. The subjects performance on both the neurobehavioral tests chosen (Y-maze and novel object recognition) did not differ significantly between the combination therapy or the monotherapy group for each treatment alone, a fact possibly explained by both the substances exerting their anti-inflammatory properties on the same pathway of NF-κB signaling[24]. In a different study, pioglitazone was administered on subjects with LPS-induced febrile seizures and subsequent memory deficits. On the treatment groups, proinflammatory markers, such as tumor necrosis factor alpha (TNF-α) and interleukine-1β (IL-1β), along with oxidative stress were reduced in the hippocampal neural tissue, with accompanying partial resolution of memory impairment and cognitive dysfunction[25]. Moreover, a meta-analysis performed by Cao *et al*[26], on the efficacy and tolerance of antidiabetic treatment as adjunct therapy on AD indicated that pioglitazone (15 to 30 mg) was the most beneficial agent (when compared to placebo) in improving cognitive capacity.

Kushwaha *et al*[27] have indicated the existence of a rosiglitazone-induced anti-apoptotic effect on cerebral cortical tissue of high-fat-diet diabetic mice, for which the underlying mechanisms have not been clearly established. PPAR-γ mediated epidermal growth factor signaling appears to be the most probable pathway by which both glial and neural cells are affected. In a similar fashion, on a model of spontaneously hypertensive rats with consequent brain damage, rosiglitazone exerted a neuroprotective effect by mediating oxidative stress and affecting the levels of apoptotic cellular pathway mediators, independent of blood pressure correction[28].

Although the anti-apoptotic effects of TZDs on neural tissue are both supported by their mode of action and have been recreated in the experimental setting, there is a current lack of clinical correlation with the molecular findings. In order to establish the possible treatment benefits of this class in DE or other neuropathologic states, there is a definite need for further studying the performance of TZD-treated subjects on functional tests assessing both cognitive capacity and memory impairment.

***Incretins***

The two antidiabetic drug classes acting on the metabolic pathway of incretin hormones are glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i). GLP-1 is a hormone with multiple effects in the gut, pancreas and neural tissues, affecting processes such as gastric motility, appetite, insulin and glucagon secretion, while DPP-4 is the enzyme that deactivates it.

***DPP-4 inhibitors***

Sitagliptin, vilagliptin, saxagliptin, linagliptin and alogliptin are the current DPP-4is being used for treatment of T2DM[29].

APP/PS1 mice having been treated with sitagliptin (20 mg/kg for an 8-wk period) underwent neurofunctional assessment with the MWM test. The treatment group presented with ameliorated functional potential attributed to upregulation of BDNF and activation of tyrosine receptor kinase B (TrkB) signaling[30]. Through similar mechanisms of BDNF and tyrosine hydroxylase upregulation, sitagliptin administered on a model of Parkinson’s disease moderated memory deficits, in addition to cellular density increase of dendritic spines in the CA1 region of the hippocampus[31]. Male Wistar rats with cisplatin-induced neurotoxicity further confirmed the neuroprotective effect of sitagliptin on both the molecular level and motor-cognitive performance, accredited to attenuation of drug-induced cerebellar damage[32].

As far as vildagliptin is concerned, upon administration in an Alzheimer’s experimental model, the substance exhibited anti-apoptotic action in the hippocampal tissue with accompanying attenuation of memory deficits, changes associated with reduced tau phosphorylation and increased expression of neurotrophic proteins. An important mediator pathway and possible treatment target, identified in the above study, was that of phosphorylated protein kinase B/p-glycogen synthase kinase 3β (Akt/GSK3β)[33]. The exact same treatment signature was observed when vildagliptin was used on a model of streptozotocin-induced T2DM with diabetes-related cognitive decline[34]. Fibroblast Growth Factor 21 (FGF21) has shown superiority when compared to vildagliptin with the study therapeutic end-points being improvement of metabolic function and neuroprotection. Despite both the substances having insulin-sensitizing, anti-apoptotic, mitochondrial and cognition-sparing properties, they differed on several other measurements. FGF21 was a more potent regulator of metabolic parameters and synaptic plasticity in the hippocampus[35].

Saxagliptin (0.25/0.5/1 mg/kg for 60 ds) has shown neuroprotective properties on streptozoticin-induced AD rats by increase of hippocampal GLP-1 levels, decrease of amyloid plaque formation and deposition[36]. A slightly different rat model of AD disease, with cognitive deficits produced by D-galactose treatment, was used as grounds for comparing the efficacy of saxagliptin and metformin on learning and memory impairment secondary to aberrant insulin signalling. Several parameters on the MWM test were improved by antidiabetic treatment, along with oxidative biomarkers, tau phosphorylation products being normalized and insulin levels dropping with concurrent insulin receptor elevation[37]. On the contrary, saxagliptin in an experimental model of Parkinson’s (produced by 6-hydroxydopamine administration) showed no cognitive- or motor-sparing properties but produced an interesting functional deterioration in the sham group, deeming it a possible candidate as post-traumatic stress disorder adjunct treatment[38].

Similar to other members of the DPP-4i class, linagliptin treatment has a beneficial role in ameliorating the progression of neural dysfunction on models of AD disease *via* numerous mechanisms such as amyloid plaque clearance, down-regulation of tau hyperphosphorylation, reduction of oxidative stress and mitochondrial dysfunction[39-41]. In T2DM test subjects, the neuroprotective attributes of the substances have been linked to changes in cerebral perfusion. In one study, linagliptin treatment post-carotid inclusion related transient cerebral ischemia attenuated cerebral damage unrelated to glucose homeostatic regulation, by mediating oxidative stress and blood brain barrier permeability[42]. Further, Hardigan *et al*[43] studied the effects of a 4-wk treatment regimen with linagliptin on vascular remodeling and flow properties of the middle cerebral arteries with beneficial effects being observed on the treatment group. The neuromodulatory role of linagliptin when compared to glimepiride is being studied by use of a composite 3-trial score (Mini-Mental State Examination, Trail Making Test, Verbal Fluency Test) in the cognition sub-study of double-blind, randomized Cardiovascular Safety of Linagliptin (CAROLINA) trial, including 4335 participants with T2DM[44].

Much like linagliptin, alogliptin has been shown to exert an effect on the architectural and functional integrity of cerebral vasculature. In a mice model of middle cerebral artery occlusion, the treatment group mediated the results of tissue ischemia and restored the defects of the blood brain barrier *via* altering the expression patterns of metalloproteinases and their inhibitors along with occludin and zona occludens-1 proteins[45]. On another model of diabetic nephropathy with silent cerebral infracts, the combination of alogliptin and hyperbaric oxygen treatment had a beneficial restorative effect on neural function[46]. Additionally, on high-fat fed doubly-negative apolipoprotein E mice with resultant cognitive decline, alogliptin up-regulated BDNF and calcineurin hippocampal production with accompanying higher performance on MWM and novel object recognition test than controls[47].

***GLP-1 receptor agonists***

The currently approved GLP-1 agonists are exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide and semaglutide.

In three studies (two included subjects with AD and one with T2DM) where the long-lasting GLP-1 analogue exenatide was used, restored BDNF signaling resulted into improved neurocognitive capacity by inhibiting neural apoptosis, in a manner analogous to that discussed on previous segments[48-50]. Bader *et al*[51] used a sustained-release preparation of the substance, named PT302, in order to study the role of exenatide treatment in TBI. Subjects in the treatment group presented with a down-regulation of pro-inflammatory markers in the neural tissue, prolonged cellular survival and reversal of functional impairment[51]. Similarly, on the topic of TBI, Rachmany *et al*[52] administered exenatide on a similar study population of mice with mild TBI, measuring both the neurofunctional changes and levels of synaptophysin (a biomarker for the viability of presynaptic neurons), pre- and post-trauma, with treatment ultimately attenuating the effects of the injury. Other changes following exenatide treatment include remodeling of hippocampal tissue architecture and diabetes-related deficits reversal, reduction of cortical TNF-α levels, preservation of brain choline acetyltransferase activity and improved amyloid oligomer clearance with subsequent decreased deposition[53,54]. A novel dual incretin agonist with combined gastric intestinal peptide and GLP-1 activity, the latter in the form of exenatide, has shown similar neuroprotective actions like memory refinement and hippocampal neurogenesis and synaptic remodeling along with a positive metabolic profile[55].

While liraglutide has been shown to effectively attenuate memory and functional deficits in subjects with various AD or similar pathology patterns in neural tissue, through mediating tau hyperphosphorylation and amyloid deposition[56-58], contradicting research does exist, in which 12-wk liraglutide treatment was not superior in cognitive function improvement when compared to placebo[59]. In the setting of cognitive decline following mood disorders, the GLP-1 RA improved performance in the Trail Making Test-B and composite Z-score of several neuropsychiatric scales measured, a change attributed to IR attenuation and other metabolic parameter modification[60]. Post-treatment behavioral normalization was also noted in a study by Koshal *et al*[61] including mice manifesting with depression secondary to seizure activity. Some of the other changes in the treatment group were the reduction of oxidative stress and seizure activity[61]. Cognitive-deficient rodents with T2DM treated with liraglutide presented with ameliorated functional potential as a result of activation and modification of downstream signaling pathways of AMPK, mTOR and phosphoinositide 3-kinase (PI3K)[62]. The involvement of the mTOR pathway in the neuroprotective action of liraglutide was further confirmed in a study of streptozotocin-induced T2DM[63].

In a manner similar to other GLP-1 RAs, a pattern of reduced proinflammatory mediators and increased amyloid plaque clearance in APP/PS1/tau mice models of AD is observed with the administration of both lixisenatide and dulaglutide, resulting in improved neurocognitive potential. The pathways involved include those of p38-MAPK, protein kinase A and Akt/PI3K[64-66]. Both the neuroprotective attributes of semaglutide and its superiority to liraglutide in improving cognition have been observed in mice models of Parkinson’s disease caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine[67,68].

***SGLT-2 inhibitors***

Sodium-glucose cotransporter 2 (SGLT2) inhibitors exert their actions on several tissue types, with their potency as antidiabetic substances stemming from their ability to hinder renal glucose reabsorption in the proximal tubule of the nephron. Members of this class currently in use are canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, tofogliflozin with sotagliflozin, a dual SGLT1/SGLT2 inhibitor, in phase III clinical trials. The relationship between neural functional capacity and memory integrity and SGLT2 inhibition has been explored in studies utilizing canagliflozin, dapagliflozin and empaglilozin.

Arafa *et al*[69] studied the effects of canagliflozin treatment on memory dysfunction secondary to scopolamine administration. As an end-result of SGLT2 inhibitor treatment, neural tissue monoamine and acetylcholine levels were increased with M1 receptor activity, a biochemical shift culminating into improved cognitive function on MWM and Y maze trials[69]. Similar patterns of altered acetylcholine signaling post-canagliflozin treatment were described on a similar study with diabetic rodents that included a metformin treatment group as well[70].

Dapagliflozin both as monotherapy and in combination with liraglutide has shown beneficial effects on memory and cognition, following remodeling of neural tissue with increased expression of doublecortin and synaptophysin (biomarkers of neural proliferation and synaptic formation respectively), as well as reduced IR[71].

The effect of empagliflozin on cognitive function was documented in the study by Lin *et al*[72], after a 9-wk regimen on db/db mice. Assessment with the MWM test and immunohistological examination of cortical tissue was subsequently performed. The cognitive function of the treatment group was superior to that of age-matched controls, with concurrent attenuation of oxidative stress and increased BDNF levels[72].

Given the relative lack of data for this antidiabetic class, combined with the fact that the possible mediating mechanisms, either direct molecular or indirect *via* modification of hemodynamic parameters, for their action on neural tissue have not been elucidated as of yet, there is definite need for further research on the subject.

***Insulin***

Neural tissue IR is an important substrate for the cognitive decline observed on diabetic subjects, especially in the hippocampal region. Numerous architectural and molecular changes fuel the pathologic process, including increased amounts of oxidative stress, activation of inflammatory cascades, peptide formation and aberrant deposition, commonly in the form of amyloid, as well as dysregulation of the hypothalamic-pituitary-adrenal axis[73]. As would be expected, since the basis of diminished functional capacity in T2DM is formed on the existence of IR, treatment with insulin, in many forms, has proven to be beneficial in ameliorating the relevant pathophysiological alterations.

Several studies have emerged, exploring the use of insulin *via* intranasal delivery, so as to bypass the blood brain barrier. This route allows for rapid achievement of therapeutic concentrations in the target tissue and treatment effectiveness, with accompanying cognitive improvement post-therapy[74-76]. Some of the proposed mechanisms for explaining the attenuation of neurofunctional deterioration caused by T2DM include altered activation of electrolyte channels (mostly calcium-related), neuropeptide expression pattern differentiation, increased clearance of peptides (hyperphosphorylated tau and Aβ) that deposit as neurofilaments, synaptic remodeling and activation, upregulation of N-methyl-D-aspartate receptors turnover and improvement of hemodynamic parameters such as neural tissue perfusion[75].

On a study performed by Maimaiti *et al*[75], short-acting insulin lispro (Humalog) and long-acting insulin detemir (Levemir) were administered intranasally on a rat model of age-related mental impairment. Both the long- and short-acting compounds were equally effective in improving memory recall, matching the performance of aged members in the treatment group, to that of young rodents in the control group[75]. Slightly different results came from the study of Benedict *et al*[77] where despite both regular and fast-acting insulin improving cognition when compared to the control group, the short-acting insulin aspart was more efficient than regular insulin in memory recall testing.

In a different research project, long-acting insulin analogs (glargine, detemir, degludec) were compared to regular insulin by use on cultured cortical neurons of rodents. Glargine, detemir and regular upregulated cortical BDNF, and activation of the Akt signaling cascade, with degludec having marginally inferior efficacy. Furthermore, regular and glargine ameliorated memory and cognition (as estimated by performance on the Y maze), showing superiority over detemir[78].

Finally, many of the physiological actions of insulin in the neural system are mediated by insulin-like growth factor-1 (IGF-1) receptors. Due to the aforementioned, similarly to insulin, use of neurostimulating factors with analogous activity on target tissues, such as IGF-1 has yielded promising results in the setting of neural proliferation and damage recovery post-trauma[79,80], neurodevelopmental disorders[81], neurovascular dysfunction[82] and IR[83].

Research data pertaining the use of insulin in the setting of cognitive decline, confirm the relationship between IR and mental deterioration, a state reversible by treatment with insulin or insulin-sensitizers. Further research could provide insight on the appropriate insulin delivery methods for achieving maximum therapeutic concentrations and treatment efficacy while minimizing risk, so as to fully utilize the potential of this therapeutic approach for diabetic and non-DE. A brief table containing all the aforementioned cognitive capacity experimental tests used on rodents is provided below (Table 1).

**CONCLUSION**

DE is term describing a multifactorial state of neural dysfunction resulting from T2DM and its hallmark, IR. Current antidiabetic regimens appear to have a beneficial effect on cognitive decline and memory impairment secondary to diabetes and other causes. Most of the research data on the subject derives from studies on metformin, TZDs and incretins, with further elucidation being required for the role and mechanisms of sodium-glucose cotransporter inhibition on neural functionality. As has been shown by the intranasal delivery of insulin, the development of vectors allowing for direct access to the CNS without inhibition from the blood-brain-barrier could open up some very interesting perspectives for repurposing the antidiabetic therapy as means to effectively treat mental dysregulation states. Moreover, the extensive elucidation of the underlying pathophysiology allowing for oral antidiabetic medication to affect neural functionality could provide insight on the reasons behind cognitive impairment in T2DM, while also allowing for formulation of proper guidelines for hinderance of its development and ultimately, treatment.

**REFERENCES**

1 **Sima AA**. Encephalopathies: the emerging diabetic complications. *Acta Diabetol* 2010; **47**: 279-293 [PMID: 20798963 DOI: 10.1007/s00592-010-0218-0]

2 **van den Berg E**, Reijmer YD, de Bresser J, Kessels RP, Kappelle LJ, Biessels GJ; Utrecht Diabetic Encephalopathy Study Group. A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus. *Diabetologia* 2010; **53**: 58-65 [PMID: 19882137 DOI: 10.1007/s00125-009-1571-9]

3 **Yaffe K**, Falvey C, Hamilton N, Schwartz AV, Simonsick EM, Satterfield S, Cauley JA, Rosano C, Launer LJ, Strotmeyer ES, Harris TB. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. *Arch Neurol* 2012; **69**: 1170-1175 [PMID: 22710333 DOI: 10.1001/archneurol.2012.1117]

4 **Chatterjee S**, Peters SA, Woodward M, Mejia Arango S, Batty GD, Beckett N, Beiser A, Borenstein AR, Crane PK, Haan M, Hassing LB, Hayden KM, Kiyohara Y, Larson EB, Li CY, Ninomiya T, Ohara T, Peters R, Russ TC, Seshadri S, Strand BH, Walker R, Xu W, Huxley RR. Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia. *Diabetes Care* 2016; **39**: 300-307 [PMID: 26681727 DOI: 10.2337/dc15-1588]

5 **MacKnight C**, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. *Dement Geriatr Cogn Disord* 2002; **14**: 77-83 [PMID: 12145454 DOI: 10.1159/000064928]

6 **Arnold SE**, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS, Craft S, Gandy S, Buettner C, Stoeckel LE, Holtzman DM, Nathan DM. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. *Nat Rev Neurol* 2018; **14**: 168-181 [PMID: 29377010 DOI: 10.1038/nrneurol.2017.185]

7 **Gray SM**, Meijer RI, Barrett EJ. Insulin regulates brain function, but how does it get there? *Diabetes* 2014; **63**: 3992-3997 [PMID: 25414013 DOI: 10.2337/db14-0340]

8 **Gantois I**, Popic J, Khoutorsky A, Sonenberg N. Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders. *Annu Rev Med* 2019; **70**: 167-181 [PMID: 30365357 DOI: 10.1146/annurev-med-081117-041238]

9 **Bang E**, Lee B, Park JO, Jang Y, Kim A, Kim S, Shin HS. The Improving Effect of HL271, a Chemical Derivative of Metformin, a Popular Drug for Type II Diabetes Mellitus, on Aging-induced Cognitive Decline. *Exp Neurobiol* 2018; **27**: 45-56 [PMID: 29535569 DOI: 10.5607/en.2018.27.1.45]

10 **Ou Z**, Kong X, Sun X, He X, Zhang L, Gong Z, Huang J, Xu B, Long D, Li J, Li Q, Xu L, Xuan A. Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice. *Brain Behav Immun* 2018; **69**: 351-363 [PMID: 29253574 DOI: 10.1016/j.bbi.2017.12.009]

11 **Tanokashira D**, Kurata E, Fukuokaya W, Kawabe K, Kashiwada M, Takeuchi H, Nakazato M, Taguchi A. Metformin treatment ameliorates diabetes-associated decline in hippocampal neurogenesis and memory via phosphorylation of insulin receptor substrate 1. *FEBS Open Bio* 2018; **8**: 1104-1118 [PMID: 29988567 DOI: 10.1002/2211-5463.12436]

12 **Mousavi F**, Eidi A, Khalili M, Roghani M. Metformin ameliorates learning and memory deficits in streptozotocin-induced diabetic rats. *J Basic Clin Pathophysiol* 2018; **6**: 17-22 [DOI: 10.22070/JBCP.2017.2782.1085]

13 **Lin Y**, Wang K, Ma C, Wang X, Gong Z, Zhang R, Zang D, Cheng Y. Evaluation of Metformin on Cognitive Improvement in Patients With Non-dementia Vascular Cognitive Impairment and Abnormal Glucose Metabolism. *Front Aging Neurosci* 2018; **10**: 227 [PMID: 30100873 DOI: 10.3389/fnagi.2018.00227]

14 **Chen JL**, Luo C, Pu D, Zhang GQ, Zhao YX, Sun Y, Zhao KX, Liao ZY, Lv AK, Zhu SY, Zhou J, Xiao Q. Metformin attenuates diabetes-induced tau hyperphosphorylation in vitro and in vivo by enhancing autophagic clearance. *Exp Neurol* 2019; **311**: 44-56 [PMID: 30219731 DOI: 10.1016/j.expneurol.2018.09.008]

15 **Mourya A**, Akhtar A, Ahuja S, Sah SP, Kumar A. Synergistic action of ursolic acid and metformin in experimental model of insulin resistance and related behavioral alterations. *Eur J Pharmacol* 2018; **835**: 31-40 [PMID: 30075220 DOI: 10.1016/j.ejphar.2018.07.056]

16 **Fatemi I**, Delrobaee F, Bahmani M, Shamsizadeh A, Allahtavakoli M. The effect of the anti-diabetic drug metformin on behavioral manifestations associated with ovariectomy in mice. *Neurosci Lett* 2019; **690**: 95-98 [PMID: 30321576 DOI: 10.1016/j.neulet.2018.10.024]

17 **Wennberg AMV**, Hagen CE, Edwards K, Roberts RO, Machulda MM, Knopman DS, Petersen RC, Mielke MM. Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging. *Int J Geriatr Psychiatry* 2018; **33**: 1114-1120 [PMID: 29873112 DOI: 10.1002/gps.4900]

18 **Thangthaeng N**, Rutledge M, Wong JM, Vann PH, Forster MJ, Sumien N. Metformin Impairs Spatial Memory and Visual Acuity in Old Male Mice. *Aging Dis* 2017; **8**: 17-30 [PMID: 28203479 DOI: 10.14336/AD.2016.1010]

19 **DiTacchio KA**, Heinemann SF, Dziewczapolski G. Metformin treatment alters memory function in a mouse model of Alzheimer's disease. *J Alzheimers Dis* 2015; **44**: 43-48 [PMID: 25190626 DOI: 10.3233/JAD-141332]

20 **Yan WW**, Chen GH, Wang F, Tong JJ, Tao F. Long-term acarbose administration alleviating the impairment of spatial learning and memory in the SAMP8 mice was associated with alleviated reduction of insulin system and acetylated H4K8. *Brain Res* 2015; **1603**: 22-31 [PMID: 25645154 DOI: 10.1016/j.brainres.2015.01.042]

21 **Ishola IO**, Akataobi OE, Alade AA, Adeyemi OO. Glimepiride prevents paraquat-induced Parkinsonism in mice: involvement of oxidative stress and neuroinflammation. *Fundam Clin Pharmacol* 2018 [PMID: 30451327 DOI: 10.1111/fcp.12434]

22 **Patel AD**, Gerzanich V, Geng Z, Simard JM. Glibenclamide reduces hippocampal injury and preserves rapid spatial learning in a model of traumatic brain injury. *J Neuropathol Exp Neurol* 2010; **69**: 1177-1190 [PMID: 21107131 DOI: 10.1097/NEN.0b013e3181fbf6d6]

23 **Esmaeili MH**, Bahari B, Salari AA. ATP-sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity, depression- and anxiety-related symptoms in a rat model of Alzheimer's disease. *Brain Res Bull* 2018; **137**: 265-276 [PMID: 29307659 DOI: 10.1016/j.brainresbull.2018.01.001]

24 **Ekladious ST**, El Sayed NS. Effect of pioglitazone and simvastatin in lipopolysaccharide-induced amyloidogenesis and cognitive impairment in mice: possible role of glutamatergic pathway and oxidative stress. *Behav Pharmacol* 2019; **30**: 5-15 [PMID: 29659380 DOI: 10.1097/FBP.0000000000000407]

25 **Hussein H**, Moghimi A, Roohbakhsh A. Anticonvulsant and ameliorative effects of pioglitazone on cognitive deficits, inflammation and apoptosis in the hippocampus of rat pups exposed to febrile seizure. *Mashhad Univ Med Sci* 2019; **22**: 267-276 [DOI: 10.22038/IJBMS.2019.35056.8339]

26 **Cao B**, Rosenblat JD, Brietzke E, Park C, Lee Y, Musial N, Pan Z, Mansur RB, McIntyre RS. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis. *Diabetes Obes Metab* 2018; **20**: 2467-2471 [PMID: 29790638 DOI: 10.1111/dom.13373]

27 **Kushwaha R**, Mishra J, Gupta AP, Gupta K, Vishwakarma J, Chattopadhyay N, Gayen JR, Kamthan M, Bandyopadhyay S. Rosiglitazone up-regulates glial fibrillary acidic protein via HB-EGF secreted from astrocytes and neurons through PPARγ pathway and reduces apoptosis in high-fat diet-fed mice. *J Neurochem* 2018 [PMID: 30311190 DOI: 10.1111/jnc.14610]

28 **Li Y**, Yu G, Liu L, Long J, Su S, Zhao T, Liu W, Shen S, Niu X. Rosiglitazone attenuates cell apoptosis through antioxidative and anti-apoptotic pathways in the hippocampi of spontaneously hypertensive rats. *Int J Mol Med* 2019; **43**: 693-700 [PMID: 30483729 DOI: 10.3892/ijmm.2018.3991]

29 **Dicker D**. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. *Diabetes Care* 2011; **34** Suppl 2: S276-S278 [PMID: 21525468 DOI: 10.2337/dc11-s229]

30 **Dong Q**, Teng SW, Wang Y, Qin F, Li Y, Ai LL, Yu H. Sitagliptin protects the cognition function of the Alzheimer's disease mice through activating glucagon-like peptide-1 and BDNF-TrkB signalings. *Neurosci Lett* 2019; **696**: 184-190 [PMID: 30597232 DOI: 10.1016/j.neulet.2018.12.041]

31 **Li J**, Zhang S, Li C, Li M, Ma L. Sitagliptin rescues memory deficits in Parkinsonian rats via upregulating BDNF to prevent neuron and dendritic spine loss. *Neurol Res* 2018; **40**: 736-743 [PMID: 29781786 DOI: 10.1080/01616412.2018.1474840]

32 **Li Y**, Zheng M, Sah SK, Mishra A, Singh Y. Neuroprotective influence of sitagliptin against cisplatin-induced neurotoxicity, biochemical and behavioral alterations in Wistar rats. *Mol Cell Biochem* 2018 [PMID: 30446906 DOI: 10.1007/s11010-018-3472-z]

33 **Ma QH**, Jiang LF, Mao JL, Xu WX, Huang M. Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer's disease. *Mol Med Rep* 2018; **17**: 4113-4119 [PMID: 29257340 DOI: 10.3892/mmr.2017.8289]

34 **Zhang DD**, Shi N, Fang H, Ma L, Wu WP, Zhang YZ, Tian JL, Tian LB, Kang K, Chen S. Vildagliptin, a DPP4 inhibitor, alleviates diabetes-associated cognitive deficits by decreasing the levels of apoptosis-related proteins in the rat hippocampus. *Exp Ther Med* 2018; **15**: 5100-5106 [PMID: 29805536 DOI: 10.3892/etm.2018.6016]

35 **Sa-Nguanmoo P**, Tanajak P, Kerdphoo S, Jaiwongkam T, Wang X, Liang G, Li X, Jiang C, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats. *Biomed Pharmacother* 2018; **97**: 1663-1672 [PMID: 29793329 DOI: 10.1016/j.biopha.2017.12.021]

36 **Kosaraju J**, Gali CC, Khatwal RB, Dubala A, Chinni S, Holsinger RM, Madhunapantula VS, Muthureddy Nataraj SK, Basavan D. Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. *Neuropharmacology* 2013; **72**: 291-300 [PMID: 23603201 DOI: 10.1016/j.neuropharm.2013.04.008]

37 **Kenawy S**, Hegazy R, Hassan A, El-Shenawy S, Gomaa N, Zaki H, Attia A. Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. *PLoS One* 2017; **12**: e0183565 [PMID: 28832656 DOI: 10.1371/journal.pone.0183565]

38 **Turnes JM**, Bassani TB, Souza LC, Vital MABF. Ineffectiveness of saxagliptin as a neuroprotective drug in 6-OHDA-lesioned rats. *J Pharm Pharmacol* 2018; **70**: 1059-1068 [PMID: 29766510 DOI: 10.1111/jphp.12936]

39 **Lin CL**, Huang CN. The neuroprotective effects of the anti-diabetic drug linagliptin against Aβ-induced neurotoxicity. *Neural Regen Res* 2016; **11**: 236-237 [PMID: 27073371 DOI: 10.4103/1673-5374.177724]

40 **Kosaraju J**, Holsinger RMD, Guo L, Tam KY. Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease. *Mol Neurobiol* 2017; **54**: 6074-6084 [PMID: 27699599 DOI: 10.1007/s12035-016-0125-7]

41 **Kornelius E**, Lin CL, Chang HH, Li HH, Huang WN, Yang YS, Lu YL, Peng CH, Huang CN. DPP-4 Inhibitor Linagliptin Attenuates Aβ-induced Cytotoxicity through Activation of AMPK in Neuronal Cells. *CNS Neurosci Ther* 2015; **21**: 549-557 [PMID: 26010513 DOI: 10.1111/cns.12404]

42 **Ma M**, Hasegawa Y, Koibuchi N, Toyama K, Uekawa K, Nakagawa T, Lin B, Kim-Mitsuyama S. DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice. *Cardiovasc Diabetol* 2015; **14**: 54 [PMID: 25986579 DOI: 10.1186/s12933-015-0218-z]

43 **Hardigan T**, Yasir A, Abdelsaid M, Coucha M, El-Shaffey S, Li W, Johnson MH, Ergul A. Linagliptin treatment improves cerebrovascular function and remodeling and restores reduced cerebral perfusion in Type 2 diabetes. *Am J Physiol Regul Integr Comp Physiol* 2016; **311**: R466-R477 [PMID: 27357799 DOI: 10.1152/ajpregu.00057.2016]

44 **Biessels GJ**, Janssen J, van den Berg E, Zinman B, Espeland MA, Mattheus M, Johansen OE; CAROLINA® investigators. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus. *BMC Neurol* 2018; **18**: 7 [PMID: 29334906 DOI: 10.1186/s12883-018-1014-7]

45 **Hao FL**, Han XF, Wang XL, Zhao ZR, Guo AH, Lu XJ, Zhao XF. The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells. *Biomed Pharmacother* 2019; **109**: 181-187 [PMID: 30396075 DOI: 10.1016/j.biopha.2018.10.064]

46 **Chen D**, Huang X, Gan H, Du X, Lu S, Huang R, Liu K, Zhang B. Efficacy of alogliptin combined with motor imagery under hyperbaric oxygen in diabetic nephropathy with silent cerebral infarction. *Biomed Rep* 2017; **7**: 407-415 [PMID: 29181153 DOI: 10.3892/br.2017.983]

47 **Mori M**, He W, Kawasaki Y, Kato N, Kasamaki Y, Kanda T. Alogliptin, DPP4 Inhibitor, Improved Cognitive and Depressive Function in Obese ApoE-/- Mice with Modification of BDNF in Hippocampus. *Int J Pharmacol* 2017; **13**: 1079-1085 [DOI: 10.3923/ijp.2017.1079.1085]

48 **Bomba M**, Granzotto A, Castelli V, Massetti N, Silvestri E, Canzoniero LMT, Cimini A, Sensi SL. Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice. *Neurobiol Aging* 2018; **64**: 33-43 [PMID: 29331730 DOI: 10.1016/j.neurobiolaging.2017.12.009]

49 **Bomba M**, Granzotto A, Castelli V, Lattanzio R, Cimini A, Sensi SL. Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease. 2018 Preprint. Available from: bioRxiv: 487629 [DOI: 10.1101/487629]

50 **Gumuslu E**, Mutlu O, Celikyurt IK, Ulak G, Akar F, Erden F, Ertan M. Exenatide enhances cognitive performance and upregulates neurotrophic factor gene expression levels in diabetic mice. *Fundam Clin Pharmacol* 2016; **30**: 376-384 [PMID: 26935863 DOI: 10.1111/fcp.12192]

51 **Bader M**, Li Y, Lecca D, Rubovitch V, Tweedie D, Glotfelty E, Rachmany L, Kim HK, Choi HI, Hoffer BJ, Pick CG, Greig NH, Kim DS. Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury. *Neurobiol Dis* 2019; **124**: 439-453 [PMID: 30471415 DOI: 10.1016/j.nbd.2018.11.023]

52 **Rachmany L**, Tweedie D, Rubovitch V, Li Y, Holloway HW, Kim DS, Ratliff WA, Saykally JN, Citron BA, Hoffer BJ, Greig NH, Pick CG. Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration. *Sci Rep* 2017; **7**: 3735 [PMID: 28623327 DOI: 10.1038/s41598-017-03792-9]

53 **Solmaz V**, Çınar BP, Yiğittürk G, Çavuşoğlu T, Taşkıran D, Erbaş O. Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. *Eur J Pharmacol* 2015; **765**: 482-487 [PMID: 26386291 DOI: 10.1016/j.ejphar.2015.09.024]

54 **Gad ES**, Zaitone SA, Moustafa YM. Pioglitazone and exenatide enhance cognition and downregulate hippocampal beta amyloid oligomer and microglia expression in insulin-resistant rats. *Can J Physiol Pharmacol* 2016; **94**: 819-828 [PMID: 27389824 DOI: 10.1139/cjpp-2015-0242]

55 **Pathak NM**, Pathak V, Gault VA, McClean S, Irwin N, Flatt PR. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential. *Biochem Pharmacol* 2018; **155**: 264-274 [PMID: 30028989 DOI: 10.1016/j.bcp.2018.07.021]

56 **McClean PL**, Jalewa J, Hölscher C. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice. *Behav Brain Res* 2015; **293**: 96-106 [PMID: 26205827 DOI: 10.1016/j.bbr.2015.07.024]

57 **Qi L**, Chen Z, Wang Y, Liu X, Liu X, Ke L, Zheng Z, Lin X, Zhou Y, Wu L, Liu L. Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β. *Am J Transl Res* 2017; **9**: 247-260 [PMID: 28337257]

58 **Batista AF**, Forny-Germano L, Clarke JR, Lyra E Silva NM, Brito-Moreira J, Boehnke SE, Winterborn A, Coe BC, Lablans A, Vital JF, Marques SA, Martinez AM, Gralle M, Holscher C, Klein WL, Houzel JC, Ferreira ST, Munoz DP, De Felice FG. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. *J Pathol* 2018; **245**: 85-100 [PMID: 29435980 DOI: 10.1002/path.5056]

59 **Watson KT**, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, McIntyre RS, Roat-Shumway S, Myoraku A, Reiss AL, Rasgon NL. Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease. *Behav Brain Res* 2019; **356**: 271-278 [PMID: 30099030 DOI: 10.1016/j.bbr.2018.08.006]

60 **Mansur RB**, Ahmed J, Cha DS, Woldeyohannes HO, Subramaniapillai M, Lovshin J, Lee JG, Lee JH, Brietzke E, Reininghaus EZ, Sim K, Vinberg M, Rasgon N, Hajek T, McIntyre RS. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. *J Affect Disord* 2017; **207**: 114-120 [PMID: 27721184 DOI: 10.1016/j.jad.2016.09.056]

61 **Koshal P**, Kumar P. Effect of Liraglutide on Corneal Kindling Epilepsy Induced Depression and Cognitive Impairment in Mice. *Neurochem Res* 2016; **41**: 1741-1750 [PMID: 27017512 DOI: 10.1007/s11064-016-1890-4]

62 **Yang Y**, Fang H, Xu G, Zhen Y, Zhang Y, Tian J, Zhang D, Zhang G, Xu J. Liraglutide improves cognitive impairment via the AMPK and PI3K/Akt signaling pathways in type 2 diabetic rats. *Mol Med Rep* 2018; **18**: 2449-2457 [PMID: 29916537 DOI: 10.3892/mmr.2018.9180]

63 **Palleria C**, Leo A, Andreozzi F, Citraro R, Iannone M, Spiga R, Sesti G, Constanti A, De Sarro G, Arturi F, Russo E. Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects. *Behav Brain Res* 2017; **321**: 157-169 [PMID: 28062257 DOI: 10.1016/j.bbr.2017.01.004]

64 **Cai HY**, Wang ZJ, Hölscher C, Yuan L, Zhang J, Sun P, Li J, Yang W, Wu MN, Qi JS. Lixisenatide attenuates the detrimental effects of amyloid β protein on spatial working memory and hippocampal neurons in rats. *Behav Brain Res* 2017; **318**: 28-35 [PMID: 27776993 DOI: 10.1016/j.bbr.2016.10.033]

65 **Cai HY**, Yang JT, Wang ZJ, Zhang J, Yang W, Wu MN, Qi JS. Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease. *Biochem Biophys Res Commun* 2018; **495**: 1034-1040 [PMID: 29175324 DOI: 10.1016/j.bbrc.2017.11.114]

66 **Mei Z**, Chen S, Guo A, Peng P, Deng Y. Dulaglutide improves learning and memory impairment, hyperphosphorylated tau and neurofilaments in the APP/PS1/tau triple transgenic mice. *Alzheimer's Dement* 2018; **14**: P348 [DOI: 10.1016/j.jalz.2018.06.185]

67 **Zhang L**, Zhang L, Li L, Hölscher C. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model. *Neuropeptides* 2018; **71**: 70-80 [PMID: 30017231 DOI: 10.1016/j.npep.2018.07.003]

68 **Zhang L**, Zhang L, Li L, Hölscher C. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease. *J Parkinsons Dis* 2019; **9**: 157-171 [PMID: 30741689 DOI: 10.3233/JPD-181503]

69 **Arafa NMS**, Ali EHA, Hassan MK. Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action. *Chem Biol Interact* 2017; **277**: 195-203 [PMID: 28837785 DOI: 10.1016/j.cbi.2017.08.013]

70 **Arafa NM**, Marie MA, AlAzimi SA. Effect of canagliflozin and metformin on cortical neurotransmitters in a diabetic rat model. *Chem Biol Interact* 2016; **258**: 79-88 [PMID: 27566243 DOI: 10.1016/j.cbi.2016.08.016]

71 **Millar P**, Pathak N, Parthsarathy V, Bjourson AJ, O'Kane M, Pathak V, Moffett RC, Flatt PR, Gault VA. Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice. *J Endocrinol* 2017; **234**: 255-267 [PMID: 28611211 DOI: 10.1530/JOE-17-0263]

72 **Lin B**, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim-Mitsuyama S. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. *Cardiovasc Diabetol* 2014; **13**: 148 [PMID: 25344694 DOI: 10.1186/s12933-014-0148-1]

73 **Biessels GJ**, Reagan LP. Hippocampal insulin resistance and cognitive dysfunction. *Nat Rev Neurosci* 2015; **16**: 660-671 [PMID: 26462756 DOI: 10.1038/nrn4019]

74 **Born J**, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. *Nat Neurosci* 2002; **5**: 514-516 [PMID: 11992114 DOI: 10.1038/nn849]

75 **Maimaiti S**, Anderson KL, DeMoll C, Brewer LD, Rauh BA, Gant JC, Blalock EM, Porter NM, Thibault O. Intranasal Insulin Improves Age-Related Cognitive Deficits and Reverses Electrophysiological Correlates of Brain Aging. *J Gerontol A Biol Sci Med Sci* 2016; **71**: 30-39 [PMID: 25659889 DOI: 10.1093/gerona/glu314]

76 **Guo Z**, Chen Y, Mao YF, Zheng T, Jiang Y, Yan Y, Yin X, Zhang B. Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer's rat model. *Sci Rep* 2017; **7**: 45971 [PMID: 28382978 DOI: 10.1038/srep45971]

77 **Benedict C**, Hallschmid M, Schmitz K, Schultes B, Ratter F, Fehm HL, Born J, Kern W. Intranasal insulin improves memory in humans: superiority of insulin aspart. *Neuropsychopharmacology* 2007; **32**: 239-243 [PMID: 16936707 DOI: 10.1038/sj.npp.1301193]

78 **Tsuneki H**, Yoshida H, Endo K, Mori N, Hosoh S, Tsuda M, Wada T, Sasaoka T. Different impacts of acylated and non-acylated long-acting insulin analogs on neural functions in vitro and in vivo. *Diabetes Res Clin Pract* 2017; **129**: 62-72 [PMID: 28511140 DOI: 10.1016/j.diabres.2017.03.032]

79 **Carlson SW**, Saatman KE. Central Infusion of Insulin-Like Growth Factor-1 Increases Hippocampal Neurogenesis and Improves Neurobehavioral Function after Traumatic Brain Injury. *J Neurotrauma* 2018; **35**: 1467-1480 [PMID: 29455576 DOI: 10.1089/neu.2017.5374]

80 **Sama DM**, Carlson SW, Joseph B, Saenger S, Metzger F, Saatman KE. Assessment of systemic administration of PEGylated IGF-1 in a mouse model of traumatic brain injury. *Restor Neurol Neurosci* 2018; **36**: 559-569 [PMID: 29889090 DOI: 10.3233/RNN-180831]

81 **Vahdatpour C**, Dyer AH, Tropea D. Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental Disorders. *Front Neurosci* 2016; **10**: 450 [PMID: 27746717 DOI: 10.3389/fnins.2016.00450]

82 **Liegl R**, Löfqvist C, Hellström A, Smith LE. IGF-1 in retinopathy of prematurity, a CNS neurovascular disease. *Early Hum Dev* 2016; **102**: 13-19 [PMID: 27650433 DOI: 10.1016/j.earlhumdev.2016.09.008]

83 **Huffman DM**, Farias Quipildor G, Mao K, Zhang X, Wan J, Apontes P, Cohen P, Barzilai N. Central insulin-like growth factor-1 (IGF-1) restores whole-body insulin action in a model of age-related insulin resistance and IGF-1 decline. *Aging Cell* 2016; **15**: 181-186 [PMID: 26534869 DOI: 10.1111/acel.12415]

**P-Reviewer:** Dabla PK, Su G **S-Editor:** Ji FF **L-Editor:** A **E-Editor:** Wu YXJ

**Specialty type:** Endocrinology and metabolism

**Country of origin:** Greece

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Experimental trials for the evaluation of cognitive capacity and memory impairment on rodent study populations**

|  |  |
| --- | --- |
| Type of test | Method of operation |
| Y-Maze Spontaneous Alternation  | Evaluates willingness of subjects to explore new paths on a 3-arm structure with each pathway angled at 120°  |
| Morris Water Maze  | Evaluates spatial and long-term memory by testing the escape capacity and velocity of subjects on a water tank |
| Passive avoidance | Evaluates learning and memory integrity by introducing aversive stimuli  |
| Rotarod | Evaluates balance and motor coordination by assessing the ability of the subject to remain standing on a rotating cylinder |
| Open field | Evaluates willingness of subjects to explore new paths, anxiety and motor coordination though observing the subject’s movement patterns on a walled-off area |
| Novel object recognition | Evaluates recognition memory though habituation of test subjects with novel objects and subsequent evaluation of their capacity to discriminate between familiar and unfamiliar. |